Open AccessIs Apelin a new biomarker in patients with polycystic ovary syndrome?
Author(s) -
Ingrid Dravecká,
Jana Figurová,
Ivica Lazúrová
Publication year - 2021
Publication title -
physiological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 70
eISSN - 1802-9973
pISSN - 0862-8408
DOI - 10.33549/physiolres.934708
Subject(s) - apelin , polycystic ovary , adipokine , insulin resistance , medicine , biomarker , endocrinology , obesity , diabetes mellitus , type 2 diabetes mellitus , metabolic syndrome , receptor , biology , biochemistry
Polycystic ovary syndrome (PCOS) is associated with multiple risk factors for cardiovascular diseases, including insulin resistance, diabetes mellitus type 2, obesity, hypertension, and dyslipidaemia. Many studies have assessed the role of adipokines in the etiopathogenesis of PCOS, however, no single biomarker has been recognized to be in causal relation to the syndrome. Apelin has been identified as a new adipokine linked to obesity and insulin resistance. Some studies demonstrated that the apelin / apelin receptor could play a pivotal role in the pathogenesis of polycystic ovary syndrome, however the other yielded controversial results. Underlying mechanisms of possible involvement of apelin/apelin receptor complex are discussed.